Friday Nov 15
Study design: two long-term observational studies of the biosimilar...
NivestimTM is a follow-on biologic agent licensed in the EU for the treatment of neutropenia and febrile neutropenia induced by myelosuppressive chemotherapy.
Stada widens biotech drug offering with filgrastim license
Germany's Stada will sell a version of U.S. drugmaker Amgen's blockbuster cancer treatment filgrastim in Europe, keeping faith with the difficult market for copies of medicines developed using biotechnology.
Research and Markets: U.S. Colony Stimulating Factors Market:...
In August 2012, the FDA approved Teva's tbo-filgrastim. The approval was based on a full Biologic License Application rather than under the FDA's new biosimilar approval pathway.
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 ...
Amgen's Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share Increased 16 Percent To $1.94 THOUSAND OAKS, Calif., Oct. 22, 2013 /PRNewswire/ -- Amgen today announced results for the third quarter of 2013.